radioiodine treatment effects on lacrimal glands function in patients with thyroid cancer [persian]

Authors

armaghan fard-esfahani

fariba akhzari

hossein mirshekarpour

mohsen saghari

mohammad eftekhari

abstract

introduction: there is a limited number of case reports published in the past decade confirming the radio-iodine presence in the tear. these observations as well as reported cases of salivary and lacrimal gland dysfunction after radioiodine therapy stimulated investigators to clarify whether lacrimal gland function can be affected post-radioiodine therapy. hence we planned a historical cohort study to evaluate this effect. methods: we studied 100 eyes of 50 patients who were referred to the nuclear medicine department of dr. shariati hospital from 01.1383 to 02.1384 and had received high doses (accumulative dose: 100-450mci) of i-131 treatment of differentiated thyroid carcinoma with their latest admission at least 3 months previously. dry eye symptoms (obtained via a standard questionnaire) and schirmer i test results (mm/5min) of this group were compared with those of an unexposed group (100 eyes of 50 individuals) matched by sex and age. cases with another known cause(s) of dry eye were not included in either group. results: 51% of the exposed eyes and 50% of the unexposed ones revealed at least one of the dry eye symptoms in the questionnaire. data analysis showed no significant difference between the number of symptoms of two groups, but 2 symptoms (burning, unrelated to light and erythema) were significantly higher in the exposed eyes. from 9 exposed eyes complaining of erythema, schirmer test result was abnormal only in 2 (one patient). also among the 10 eyes with burning symptom (unrelated to light) one patient (2 eyes) revealed abnormal schirmer test result. the study also demonstrated a significantly lower wetting amount of the schirmer paper in exposed group compared to others. in the patients undergone radio-iodine therapy, results were 0-4 mm in 21%, 5-9 mm in 20% and 10 mm or more in 59%. these results were seen in the unexposed group in 6%, 17% and 77%, respectively. file review of the 21 exposed eyes with 0-4 mm schirmer test results revealed presence of the migraine history in five (4 woman) surprisingly and 131i-avid skull metastasis in another patient (2 eyes). conclusion: long-term reduction in the tear secretion from major and/or minor lacrimal glands is seen after high-dose radio-iodine therapy, which seems to be severe in the majority of patients; however these patients complain of dry eye symptoms no more than unexposed population. conditions such as migraine may be unknown causes of impaired tear secretion and need further investigation.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Radioiodine treatment effects on lacrimal glands function in patients with thyroid cancer [Persian]

  Introduction: There is a limited number of case reports published in the past decade confirming the radio-iodine presence in the tear. These observations as well as reported cases of salivary and lacrimal gland dysfunction after radioiodine therapy stimulated investigators to clarify whether lacrimal gland function can be affected post-radioiodine therapy. Hence we ...

full text

Radioiodine therapy effects on salivary gland function in patients with differentiated thyroid cancer [Persian]

Salivary gland involvement is one of the radioiodine therapy complications. Salivary gland scintigraphy in quantitative mode can accurately evaluate salivary gland function. Methods: Salivary gland scintigraphy was performed with Tc-99m Pertechnetate, at the time of iodine therapy as a basic study and then 3 weeks and 3 months afterwards. Ejection Fraction (EF) of parotid and submandibula...

full text

radioiodine therapy effects on salivary gland function in patients with differentiated thyroid cancer [persian]

salivary gland involvement is one of the radioiodine therapy complications. salivary gland scintigraphy in quantitative mode can accurately evaluate salivary gland function. methods: salivary gland scintigraphy was performed with tc-99m pertechnetate, at the time of iodine therapy as a basic study and then 3 weeks and 3 months afterwards. ejection fraction (ef) of parotid and submandibular glan...

full text

Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer

The aim of this study was to evaluate the effects of the first radioactive iodine (I) therapy on functions of salivary glands in patients with differentiated thyroid carcinoma (DTC).There were 36 consented patients with DTC enrolled in this study, who received 3.7 GBq (100mCi) I for ablation after total thyroidectomy. Salivary gland function was assessed using salivary gland scintigraphy in two...

full text

Effects of treatment with radioiodine (¹³¹I) on the gonadal function of the hyperthyroid patients

Introduction: Hyperthyroidism is a relatively common disorder caused by different etiologies. Graves’ disease, and toxic-nodular goiter (Plummer’s disease) are among the most common causes. Treatment with radioiodine is considered to be the treatment of choice in many of the patients. Higher biological half-life of ¹³¹I in hyperthyroid patients as compared with patients with differentiate...

full text

Evaluation the early effects of single high dose radioiodine therapy on lacrimal gland function

Background: The therapeutic administration of 131I for thyroid remnant ablation and for metastases comes up with some adverse effects. This study was conducted to investigate whether single high dose radioiodine therapy affects lacrimal gland functions or not. Materials and Methods: Seventy-eight eyes of 39 patients, who were diagnosed as differentiated thyroid carcinoma, were objectively teste...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of nuclear medicine

Publisher: tehran university of medical sciences

ISSN 1681-2824

volume 13

issue 2 2005

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023